Home » FDA Revises Hotline Ad Study in Response to Industry Input
FDA Revises Hotline Ad Study in Response to Industry Input
The FDA will expand a study of TV drug advertising to determine the effectiveness of listing a consumer hotline for reporting adverse events, based on drug industry comments. The FDA Amendments Act calls for the agency to determine whether consumers understand and remember messages about the toll-free hotline in direct-to-consumer TV ads. The agency now plans to show mock TV ads to 6,000 participants compared with the 1,600 it originally planned to enlist, according to a recent notice in the Federal Register.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
07May
-
14May
-
30May